TEXAS BIOMEDICAL RESEARCH INSTITUTE: Single Audit Reports and Findings
TEXAS BIOMEDICAL RESEARCH INSTITUTE filed 10 single audits between 2016 and 2025; the most recently observed auditor is ERNST & YOUNG LLP (2025), and the 2025 report lists 67 findings. Data as of 2026-09-17.
Data as of Sep 17, 2026 · Source: Federal Audit Clearinghouse (public data)
Single audits by year
One row per audit year as the Federal Audit Clearinghouse accepted it. The auditor named is the one observed on that filing; TEXAS BIOMEDICAL RESEARCH INSTITUTE is recorded in SAN ANTONIO, Texas under EIN 741109630, and the Clearinghouse records it as a nonprofit.
| Audit year | Fiscal year end | Federal expended | Threshold applied | Auditor observed | Findings | MW / SD | FAC report |
|---|---|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $54,077,608 | $1,622,328 | ERNST & YOUNG LLP | 67 | — | 2025-12-GSAFAC-0000420793 |
| 2024 | 2024-12-31 | $45,600,408 | $1,368,012 | ERNST & YOUNG LLP | 11 | SD | 2024-12-GSAFAC-0000381780 |
| 2023 | 2023-12-31 | $48,586,140 | $1,457,584 | ERNST & YOUNG LLP | 16 | SD | 2023-12-GSAFAC-0000054769 |
| 2022 | 2022-12-31 | $38,129,999 | $1,143,900 | ERNST & YOUNG LLP | 12 | SD | 2022-12-CENSUS-0000101110 |
| 2021 | 2021-12-31 | $34,454,598 | $1,033,638 | ERNST & YOUNG LLP | 0 | — | 2021-12-CENSUS-0000101110 |
| 2020 | 2020-12-31 | $34,077,564 | $1,022,327 | ERNST & YOUNG LLP | 0 | — | 2020-12-CENSUS-0000101110 |
| 2019 | 2019-12-31 | $34,194,652 | $1,025,840 | ERNST & YOUNG LLP | 0 | — | 2019-12-CENSUS-0000101110 |
| 2018 | 2018-12-31 | $32,279,060 | $968,372 | ERNST & YOUNG LLP | 50 | SD | 2018-12-CENSUS-0000101110 |
| 2017 | 2017-12-31 | $32,352,780 | $970,583 | ERNST & YOUNG LLP | 58 | SD | 2017-12-CENSUS-0000101110 |
| 2016 | 2016-12-31 | $30,563,607 | $916,908 | ERNST & YOUNG LLP | 48 | SD | 2016-12-CENSUS-0000101110 |
Which federal programs did this organization report?
From the most recent accepted report. "Major" is the designation the auditor made under 2 CFR 200.518, not ours.
| ALN | Program | Expended | Major |
|---|---|---|---|
| 93.855 | ALLERGY AND INFECTIOUS DISEASES RESEARCH | $14,500,757 | Yes |
| 93.351 | RESEARCH INFRASTRUCTURE PROGRAMS | $10,424,772 | Yes |
| 93.RD | Correlate of Protection (CoP) Studies to Support Development of the cAd3-EBO-S (Sudan virus) Candidate Vaccine | $4,962,039 | Yes |
| 12.351 | SCIENTIFIC RESEARCH - COMBATING WEAPONS OF MASS DESTRUCTION | $2,459,620 | Yes |
| 93.RD | BARDA RTOR BIO-AMT-2301: IDIQ Contact Management Support Activities | $2,298,211 | Yes |
| 93.352 | CONSTRUCTION SUPPORT | $2,223,741 | Yes |
| 11.307 | ECONOMIC ADJUSTMENT ASSISTANCE | $2,033,086 | Yes |
| 93.242 | MENTAL HEALTH RESEARCH GRANTS | $1,245,085 | Yes |
| 93.279 | DRUG USE AND ADDICTION RESEARCH PROGRAMS | $1,006,570 | Yes |
| 93.855 | ALLERGY AND INFECTIOUS DISEASES RESEARCH | $824,461 | Yes |
| 93.855 | ALLERGY AND INFECTIOUS DISEASES RESEARCH | $757,190 | Yes |
| 93.855 | ALLERGY AND INFECTIOUS DISEASES RESEARCH | $556,571 | Yes |
| 12.910 | RESEARCH AND TECHNOLOGY DEVELOPMENT | $519,438 | Yes |
| 93.855 | ALLERGY AND INFECTIOUS DISEASES RESEARCH | $500,822 | Yes |
| 93.RD | Efficacy studies in SUDV (Gulu variant) challenged Rhesus macaque non-human primates (NHP) | $482,352 | Yes |
| 93.279 | DRUG USE AND ADDICTION RESEARCH PROGRAMS | $441,845 | Yes |
| 93.242 | MENTAL HEALTH RESEARCH GRANTS | $435,479 | Yes |
| 93.866 | AGING RESEARCH | $430,004 | Yes |
| 93.RD | Strong Heart Study Cardiovascular Center | $390,730 | Yes |
| 93.855 | ALLERGY AND INFECTIOUS DISEASES RESEARCH | $389,450 | Yes |
| 93.859 | BIOMEDICAL RESEARCH AND RESEARCH TRAINING | $374,920 | Yes |
| 93.855 | ALLERGY AND INFECTIOUS DISEASES RESEARCH | $371,821 | Yes |
| 93.279 | DRUG USE AND ADDICTION RESEARCH PROGRAMS | $354,745 | Yes |
| 12.420 | MILITARY MEDICAL RESEARCH AND DEVELOPMENT | $321,279 | Yes |
| 93.RD | Efficacy Testing of a Marburg Virus Monoclonal Antibody Medical Countermeasure | $314,452 | Yes |
What findings did the auditor report?
The reference and the requirement letter are the ones the auditor used. The finding text itself is not reproduced here; the FAC report linked above carries it in full.
| Reference | Requirement | Severity | Repeat |
|---|---|---|---|
| 2025-001 | I | Material weakness / Questioned costs | Yes |
Form 990 and IRS registration
Form 990 "accounting fees" (Part IX line 11c) cover all accounting services reported by the organization and are not the price of an audit engagement.
- Most recent return
- 990 for 2024-12
- Total revenue
- $75,183,345
- Total assets
- $366,564,882
- Accounting fees (Part IX line 11c)
- $162,506
- Paid preparer
- RSM US LLP
- IRS object id
- 202523169349307837
- NTEE code
- H40
- Exempt under
- 501(c)(3)
- Ruling year
- 1953
- BMF release
- 2026-09-17
Read next
How we computed this
Every row comes from the Federal Audit Clearinghouse record named beside it, one report per audit year, with a resubmission superseding the filing it replaces. The auditor is the one named on that filing — it is not a statement about who audits TEXAS BIOMEDICAL RESEARCH INSTITUTE now. Form 990 figures come from the IRS e-filed return named by its object id. This page exists because the organization filed at least two single audits, or one with a finding.
Cite this page
AuditRadar. “TEXAS BIOMEDICAL RESEARCH INSTITUTE Single Audits.” https://getauditradar.com/single-audits/tx/texas-biomedical-research-institute-741109630/. Data as of 2026-09-17.